Database : MEDLINE
Search on : Polyneuropathies [Words]
References found : 25479 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 2548 go to page                         

  1 / 25479 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 28449973
[Au] Autor:Sandhu SK; Hua W; MaCurdy TE; Franks RL; Avagyan A; Kelman J; Worrall CM; Ball R; Nguyen M
[Ad] Address:Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. Electronic address: sukhminder.sandhu@fda.hhs.gov.
[Ti] Title:Near real-time surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2010/11 to 2013/14.
[So] Source:Vaccine;35(22):2986-2992, 2017 05 19.
[Is] ISSN:1873-2518
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:BACKGROUND: Guillain-Barré syndrome (GBS) is a serious acute demyelinating disease that causes weakness and paralysis. The Food and Drug Administration (FDA) began collaborating with the Centers for Medicare and Medicaid Services (CMS) to develop near real-time vaccine safety surveillance capabilities in 2006 and has been monitoring for the risk of GBS after influenza vaccination for every influenza season since 2008. METHODS: We present results from the 2010/11 to 2013/14 influenza seasons using the Updating Sequential Probability Ratio Test (USPRT), with an overall 1-sided α of 0.05 apportioned equally using a constant alpha-spending plan among 20 consecutive weekly tests, 5 ad hoc tests, and a 26th final end of season test. Observed signals were investigated using the self-controlled risk interval (SCRI) design. RESULTS: Over 15 million people were vaccinated in each influenza season. In the 2010/11 influenza season, we observed an elevated GBS risk during the season, with an end of season SCRI analysis finding a nonsignificant increased risk (RR=1.25, 95% CI: 0.96-1.63). A sensitivity analysis applying the positive predictive value of the ICD-9 code for GBS from the 2009/10 season estimated a RR=1.98 (95% CI: 1.42-2.76). Although the 2010/11 influenza vaccine suggested an increased GBS risk, surveillance of the identical vaccine in the 2011/12 influenza season did not find an increased GBS risk after vaccination. No signal was observed in the subsequent three influenza seasons. CONCLUSIONS: Conducting near real-time surveillance using USPRT has proven to be an excellent method for near real-time GBS surveillance after influenza vaccination, as demonstrated by our surveillance efforts during the 2010/11-2013/14 influenza seasons. In the 2010/2011 influenza season, in addition to the 2009 H1N1 influenza pandemic, using near real-time surveillance we were able to observe a signal early in the influenza season and the method has now become routine.
[Mh] MeSH terms primary: Guillain-Barre Syndrome/epidemiology
Influenza Vaccines/adverse effects
Medicare
Population Surveillance/methods
[Mh] MeSH terms secundary: Aged
Aged, 80 and over
Centers for Medicare and Medicaid Services (U.S.)
Computer Systems
Female
Guillain-Barre Syndrome/etiology
Humans
Influenza Vaccines/administration & dosage
Male
Risk Assessment
United States/epidemiology
United States Food and Drug Administration
Vaccination
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Influenza Vaccines)
[Em] Entry month:1802
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:170429
[St] Status:MEDLINE

  2 / 25479 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29429161
[Au] Autor:Li L; Duan XJ; Sun Y; Lu Y; Xu HY; Wang QZ; Wang HY
[Ad] Address:Department of Pathology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China.
[Ti] Title:[Classification of cardiac amyloidosis: an immunohistochemical analysis].
[So] Source:Zhonghua Bing Li Xue Za Zhi;47(2):105-109, 2018 Feb 08.
[Is] ISSN:0529-5807
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:To evaluate the sensitivity and specificity of immunohistochemistry (IHC) in the classification of cardiac amyloidosis on endomyocardial biopsy (EMB) and heart allograft. Twenty cardiac tissues from 19 patients at Fuwai Hospital from January, 1990 to April, 2017 with histopathologic features of amyloidosis and Congo red staining positivity were included. IHC was performed with monoclonal antibodies against AA amyloid and polyclonal antibodies against transthyretin (ATTR), λ-light chain (AL-λ), κ-light chain (AL-κ), ApoAâ… , ApoAâ…¡, ApoA â…£ and ß(2)-microglobin. The extent of interstitial staining was evaluated by light microscopy, and three patterns were recognized; these included diffuse pericellular pattern, discrete pericellular pattern, and nodular pattern. Two patterns of vascular deposition were also noted, including arterial pattern and venous pattern. Endocardial involvement was also assessed and recorded. Nineteen cases were divided into three groups according to the pattern of proteins expression in specimens. The first group (5 cases) only showed single protein expression on EMB. The second group (6 cases) showed more than one protein expression, but one of them was intensely stained or any staining of any protein together with ApoA â…£ co-staining. The third group (8 cases) also showed more than one protein expression and all of them had intense staining. Amyloid deposits were successfully subtyped as AL-λ, ATTR, AL-κ and ApoAâ… by IHC in the former two groups with the sensitivity of 11/19. In the third group, amyloid deposits could not be subtyped by immunohistochemistry due to their poor specificity. The pericellular pattern tended to favor AL over ATTR amyloidosis and vascular deposition tended to favor ATTR. Amyloid deposits can be reliably subtyped in diagnostic cardiac specimens using IHC. The co-deposition of chaperon proteins, the distribution of amyloid proteins and clinical features are also auxiliary to subtype cardiac amyloidosis.
[Mh] MeSH terms primary: Amyloidosis/pathology
Cardiomyopathies/pathology
[Mh] MeSH terms secundary: Amyloid/analysis
Amyloid Neuropathies, Familial/pathology
Antibodies, Monoclonal/analysis
Apolipoprotein A-I/analysis
Apolipoproteins A/analysis
Biopsy
Humans
Immunoglobulin kappa-Chains/analysis
Immunoglobulin lambda-Chains/analysis
Immunohistochemistry
Plaque, Amyloid/pathology
Sensitivity and Specificity
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (APOA1 protein, human); 0 (Amyloid); 0 (Antibodies, Monoclonal); 0 (Apolipoprotein A-I); 0 (Apolipoproteins A); 0 (Immunoglobulin kappa-Chains); 0 (Immunoglobulin lambda-Chains); 0 (apolipoprotein A-IV)
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[Js] Journal subset:IM
[Da] Date of entry for processing:180213
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0529-5807.2018.02.005

  3 / 25479 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29372388
[Au] Autor:Langjahr M; Schubert AL; Sommer C; Üçeyler N
[Ad] Address:Department of Neurology, University of Würzburg, Josef-Schneider-Str. 11, 97080, Würzburg, Germany.
[Ti] Title:Increased pro-inflammatory cytokine gene expression in peripheral blood mononuclear cells of patients with polyneuropathies.
[So] Source:J Neurol;265(3):618-627, 2018 Mar.
[Is] ISSN:1432-1459
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:BACKGROUND: Distinct cytokine expression patterns have been reported in biomaterial of patients with polyneuropathies (PNP). We investigated gene expression profiles of pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells (PBMC) of patients with neuropathies of different etiologies. METHODS: We prospectively studied 97 patients with neuropathies and compared data between diagnostic subgroups and healthy controls. Gene expression of a panel of pro- and anti-inflammatory cytokines was analyzed (interleukin-1 [IL-1], IL-2, IL-6, IL-8, tumor necrosis factor alpha [TNF], IL-4, and IL-10) in PBMC samples. Furthermore, protein levels of IL-6, IL-8, and TNF were measured in supernatant of PBMC stimulated with lipopolysaccharide (LPS). RESULTS: PNP were associated with higher PBMC gene expression of IL-1 (p < 0.05), IL-2 (p < 0.05), IL-8 (p < 0.001), and TNF (p < 0.01) compared to healthy controls. Inflammatory neuropathies were associated with higher gene expression of IL-8 (p < 0.001) and TNF (p < 0.05) and lower gene expression of IL-10 (p < 0.05) compared to healthy controls. More pro-inflammatory cytokines were elevated in painful neuropathy (IL-1, IL-2 [p < 0.05], IL-8 [p < 0.001] and TNF [p < 0.05]) than in painless neuropathy (IL-8 [p < 0.01] and TNF [p < 0.01]) compared to healthy controls, while IL-10 expression was higher in treatment naïve patients with painless neuropathy compared to patients with painful neuropathy (p < 0.05). Disease duration positively correlated with IL-6 gene expression (p < 0.01). Supernatant protein levels of IL-6, IL-8, and TNF did not differ between groups. CONCLUSION: Systemic gene expression of pro-inflammatory cytokines is increased in patients with neuropathies and may be influenced by the presence of neuropathic pain.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Process
[do] DOI:10.1007/s00415-018-8748-4

  4 / 25479 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29506297
[Au] Autor:Steindorf K; Schmidt ME; Zimmer P
[Ti] Title:Sport und Bewegung mit und nach Krebs ­ wer profitiert, was ist gesichert? [Exercise and Physical Activity During and after Cancer - Who Benefits most, What is Proven?]
[So] Source:Dtsch Med Wochenschr;143(5):309-315, 2018 Mar.
[Is] ISSN:1439-4413
[Cp] Country of publication:Germany
[La] Language:ger
[Ab] Abstract:A growing number of literature reports positive effects of physical activity and exercise. These effects concern prevention, mortality and progress of cancer. Furthermore they show a reduction of disease- and treatment-specific side effects, which implies a better patients' quality of life. Evidence shows a decreased mortality risk in patients with physically active cancer of colon, breast, ovaries and prostate. Activity recommendations for patients with cancer do not differ from those for healthy persons. However, a decrease in physical activity can be observed in many cancer patients after diagnosis, and this fact concludes to a reduced physical capacity - although just physical capacity helps to overcome the burden of medical treatment and to recover. In fact, tailored exercise programs can counteract a decrease in physical capacity successfully. Further they reduce side effects such as fatigue, incontinence and lymphedema. Moreover, first studies report a positive influence on: chemotherapy-induced polyneuropathies, cancer-related cognitive impairments, bone health and sleep. Finally, an enormous number of investigations showed that exercise interventions can improve psychosocial factors (e. g. mood and self-esteem). Except for very few conditions, such as extremely impaired blood cell counts and days when cardio- or nephrotoxic drugs are given, physical activity should be recommended. Especially during medical treatment, physicians and therapists are prompted to interact closely in order to prevent general activity prohibitions. Physical activity and exercise programs represent a unique and low-cost chance for cancer patients to influence the course of their own disease positively. More effort is necessary to improve professional activity offers for cancer patients and survivors and to specify activity recommendations.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[St] Status:In-Data-Review
[do] DOI:10.1055/s-0043-106885

  5 / 25479 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29390370
[Au] Autor:Chen JH; Lee KY; Hu CJ; Chung CC
[Ad] Address:Department of Neurology.
[Ti] Title:Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
[So] Source:Medicine (Baltimore);96(50):e9262, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Immune checkpoint inhibitors have led to the development of new approaches for cancer treatment with positive outcomes. However, checkpoint blockade is associated with a unique spectrum of immune-related adverse events (irAEs), which may cause irreversible neurological deficits and even death. PATIENT CONCERNS: We presented a case of a 57-year-old man with non-small-cell lung cancer.who developed ptosis, dyspnea, and muscle weakness as initial symptoms with progression after the treatment with ipilimumab and nivolumab. DIAGNOSES: Myasthenia gravis was confirmed by serum acetylcholine receptor antibody and single fiber electromyography. Myositis was identified by high level of serum creatine phosphokinase and electromyography. Polyneuropathy was identified by nerve conduction study. INTERVENTIONS: The patient underwent treatment with steroid and pyridostigmine. Respiratory rehabilitation was also performed. OUTCOMES: Dyspnea and muscle weakness improved gradually. Ipilimumab and nivolumab were permanently discontinued. LESSONS: This case has increased the clinical awareness by indicating that the checkpoint inhibitors-related neurological irAEs could be complicated and simultaneously involve multiple neurological systems. Early recognition and complete evaluation are critical in clinical practice.
[Mh] MeSH terms primary: Antibodies, Monoclonal/adverse effects
Antineoplastic Agents, Immunological/adverse effects
Carcinoma, Non-Small-Cell Lung/drug therapy
Ipilimumab/adverse effects
Lung Neoplasms/drug therapy
Myasthenia Gravis/chemically induced
Myositis/chemically induced
Polyneuropathies/chemically induced
[Mh] MeSH terms secundary: Humans
Male
Middle Aged
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents, Immunological); 0 (Ipilimumab); 31YO63LBSN (nivolumab)
[Em] Entry month:1802
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009262

  6 / 25479 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29442005
[Au] Autor:Petroianu GA
[Ti] Title:Neuropathic organophosphates: from Scrugham, Heim and Lorot to Jake leg paralysis.
[So] Source:Pharmazie;71(12):738-744, 2016 Dec 01.
[Is] ISSN:0031-7144
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:Henry Scrugham (1811-1898), the father of triphenyl-phosphate, was a student of Alexander Williamson (1824-1904), Professor of analytical and practical chemistry at the University College London. Williamson using the approach perfected by Scurgham reacted phosphorus pentachloride with cresol (a mixture of ortho, para and meta isomers) thus obtaining tricresyl phosphate (TCP). The triesters of phenol, cresol and naphtol were prepared with a higher yield by Rudolf Heim (1861-1919) by their respective reaction with phosphorus oxychloride (POCl3). Heim is also the first one to obtain pure tri-o-cresyl phosphate (TOCP). In the meantime French pharmacist Jules Brissonnet (1859-1915) synthesized creosote phosphate (containing i.a. TOCP) and popularized its use in the treatment of pulmonary phthisis (tuberculosis). Camille Lorot (1872-1951) and others in France and Germany recognized the ability of creosote phosphate to induce polyneuropathies but this knowledge did not prevent the Ginger Jake epidemic (Jake leg) of the 1930s in the US. The Jake induced neuropathy was first recognized and described in Oklahoma City by a General Practitioner, Ephraim Goldfain (1894-1983). Soon thereafter Maurice Isadore Smith (1887-1951), a pharmacologist, and chemist Elias Elvove (1883-1962) identified TOCP in Jamaican ginger extract as the causative agent. We attempt to shed some light on the life and family of the less known chemists, pharmacists and physicians associated with the synthesis of neuropathic organophosphates and with the recognition of their toxicity.
[Mh] MeSH terms primary: Neurotoxicity Syndromes/history
Organophosphates/toxicity
[Mh] MeSH terms secundary: History, 19th Century
History, 20th Century
Neurotoxicity Syndromes/pathology
Organophosphates/chemical synthesis
[Pt] Publication type:BIOGRAPHY; HISTORICAL ARTICLE; JOURNAL ARTICLE; PORTRAITS
[Ps] Personal name as subject:Scrugham H; Heim R; Brissonnet J; Goldfain E; Elvove E; Smith M
[Nm] Name of substance:0 (Organophosphates)
[Em] Entry month:1802
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[Js] Journal subset:IM
[Da] Date of entry for processing:180215
[St] Status:MEDLINE
[do] DOI:10.1691/ph.2016.6080

  7 / 25479 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29478436
[Au] Autor:Sommer C; Geber C; Young P; Forst R; Birklein F; Schoser B
[Ad] Address:Department of Neurology, University Hospital Würzburg; DRK Pain Center Mainz; Department of Sleep Medicine and Neuromuscular Disorders, Münster University; University Orthopedic Clinic Erlangen; Department of Neurology, University Hospital Mainz; Friedrich-Baur Institute, Department of Neurology, Ludwig-Maximilians-Universität Munich.
[Ti] Title:Polyneuropathies.
[So] Source:Dtsch Arztebl Int;115(6):83-90, 2018 Feb 09.
[Is] ISSN:1866-0452
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:BACKGROUND: Polyneuropathies (peripheral neuropathies) are the most common type of disorder of the peripheral nervous system in adults, and specifically in the elderly, with an estimated prevalence of 5-8%, depending on age. The options for treatment depend on the cause, which should therefore be identified as precisely as possible by an appropriate diagnostic evaluation. METHODS: This review is based on the current guidelines and on large-scale cohort studies and randomized, controlled trials published from 2000 to 2017, with an emphasis on non-hereditary types of polyneuropathy, that were retrieved by a selective search in PubMed. RESULTS: Diabetes is the most common cause of polyneuropathy in Europe and North America. Alcohol-associated polyneuropathy has a prevalence of 22-66% among persons with chronic alcoholism. Because of the increasing prevalence of malignant disease and the use of new chemotherapeutic drugs, chemotherapy-induced neuropathies (CIN) have gained in clinical importance; their prevalence is often stated to be 30-40%, with high variation depending on the drug(s) and treatment regimen used. Polyneuropathy can also arise from genetic causes or as a consequence of vitamin deficiency or overdose, exposure to toxic substances and drugs, and a variety of immunological processes. About half of all cases of polyneu - ropathy are associated with pain. Neuropathic pain can be treated symptomatically with medication. Exercise, physiotherapy, and ergotherapy can also be beneficial, depending on the patient's symptoms and functional deficits. CONCLUSION: A timely diagnosis of the cause of polyneuropathy is a prerequisite for the initiation of appropriate specific treatment. Patients with severe neuropathy of unidentified cause should be referred to a specialized center for a thorough diagnostic evaluation.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180226
[Lr] Last revision date:180226
[St] Status:In-Data-Review

  8 / 25479 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28454586
[Au] Autor:Pan JH; Peng CY; Lo CT; Dai CY; Wang CL; Chuang HY
[Ad] Address:Department of Occupational & Environmental Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. euphyflower1227@gmail.com.
[Ti] Title:n-Hexane intoxication in a Chinese medicine pharmaceutical plant: a case report.
[So] Source:J Med Case Rep;11(1):120, 2017 Apr 28.
[Is] ISSN:1752-1947
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: n-Hexane is a well-known neurotoxicant. Polyneuropathy due to occupational n-hexane exposure has been reported worldwide, however, our case is the first report in the Chinese herb industry. CASE PRESENTATION: A 25-year-old Asian man experienced progressive weakness and numbness in his hands and feet after working as an operator in a Chinese medicine pharmaceutical plant for the manufacture of Chinese herbal pain relief patches for 10 months. Electrophysiological studies indicated a reduction in nerve conduction velocity, prolongation of distal latencies, mildly positive sharp waves, and reduced recruitment with polyphasic potentials, particularly at distal sites. Demyelination with axonal degeneration caused by occupational n-hexane exposure was strongly suspected. Through investigation of our patient's workplace, the ambient n-hexane concentration in air was found to considerably exceed the permissible exposure limit/time-weighted average for n-hexane in Taiwan. His symptoms were gradually relieved after 4 months of cessation of exposure to n-hexane. He was then confirmed as a case of occupational n-hexane intoxication. Further effective control measures should be implemented as soon as possible to prevent exposure of workers to n-hexane. CONCLUSIONS: Despite a typical clinical presentation, his exposure at workplace was appropriately investigated. Chemical exposure in Chinese medicine pharmaceutical plants could be an emerging issue that may affect workers' health. The lack of knowledge and management of solvents could endanger the health of workers. This case has profound educational implications for occupational health and is worthy of further follow-up for improving hazards control.
[Mh] MeSH terms primary: Asian Continental Ancestry Group
Drugs, Chinese Herbal/chemistry
Hexanes/poisoning
Occupational Diseases/chemically induced
Occupational Exposure/adverse effects
Polyneuropathies/chemically induced
[Mh] MeSH terms secundary: Adult
Humans
Male
Occupational Diseases/physiopathology
Plants, Medicinal/chemistry
Polyneuropathies/physiopathology
Recovery of Function
Taiwan
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Drugs, Chinese Herbal); 0 (Hexanes); 2DDG612ED8 (n-hexane)
[Em] Entry month:1802
[Cu] Class update date: 180221
[Lr] Last revision date:180221
[Js] Journal subset:IM
[Da] Date of entry for processing:170430
[St] Status:MEDLINE
[do] DOI:10.1186/s13256-017-1280-9

  9 / 25479 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29194856
[Au] Autor:Abraham A; Barnett C; Katzberg HD; Lovblom LE; Perkins BA; Bril V
[Ad] Address:Neuromuscular Service of the Department of Neurology, Tel Aviv Sourasky Medical Center, The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
[Ti] Title:Toronto Clinical Neuropathy Score is valid for a wide spectrum of polyneuropathies.
[So] Source:Eur J Neurol;25(3):484-490, 2018 Mar.
[Is] ISSN:1468-1331
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND AND PURPOSE: The Toronto Clinical Neuropathy Score (TCNS) is a valid and reliable scale for the diagnosis and staging of diabetic sensorimotor polyneuropathy. In this study, we aimed to explore the performance of the TCNS in non-diabetic polyneuropathies. METHODS: We performed a prospective study from November 2016 to May 2017 of patients with non-diabetic polyneuropathy. Patients had clinical, electrophysiological and functional assessments of their polyneuropathy, and the findings were correlated with the TCNS. RESULTS: The TCNS correlated with all clinical, electrophysiological and disability measures of polyneuropathy, mostly at a moderate level (e.g. r = -0.58 for sural nerve action potential amplitude). Higher TCNS severity grades were associated with worse polyneuropathy on all measures in the lower limbs, and with worse electrophysiological parameters and vibration perception thresholds in the upper limbs. The scale also showed excellent reliability and accuracy (kappa, 0.92-0.93 for inter- and intra-observer reliability; area under the receiver operating characteristics curve, 0.93). CONCLUSION: The TCNS is a valid and reliable scale for a wide spectrum of polyneuropathies, and might be useful in clinical practise and research for the diagnosis and staging of polyneuropathy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180221
[Lr] Last revision date:180221
[St] Status:In-Data-Review
[do] DOI:10.1111/ene.13533

  10 / 25479 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29455455
[Au] Autor:Franciotta D; Gastaldi M; Zardini E; Nobile-Orazio E
[Ad] Address:Laboratory of Neuroimmunology, IRCCS Mondino Foundation, Pavia, Italy.
[Ti] Title:Cerebrospinal fluid total protein determination in acute and chronic inflammatory demyelinating polyneuropathies: a critical reappraisal.
[So] Source:J Peripher Nerv Syst;, 2018 Feb 18.
[Is] ISSN:1529-8027
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1802
[Cu] Class update date: 180218
[Lr] Last revision date:180218
[St] Status:Publisher
[do] DOI:10.1111/jns.12253


page 1 of 2548 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information